Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligands
US6605279B2 · kind B2 · utility
11Cited by
7References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 22, 1999 |
| Grant date | Aug 12, 2003 |
| Priority date | — |
| Expiry date | Oct 22, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a composition for inhibiting the interactions of B7-1 and B7-2 with their natural ligands. Such compositions comprise an antibody specific for B7-2 and an antibody specific for B7-1, in a pharmaceutically acceptable carrier. The composition may be formulated for either separate or combined administration of the antibody components. The antibodies may be monoclonal antibodies, or humanized antibodies. Preferred antibodies are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.